Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 364

Results For "SSI"

5617 News Found

ASG Eye Hospitals enters Haryana and expands footprint in UP
Healthcare | November 10, 2022

ASG Eye Hospitals enters Haryana and expands footprint in UP

ASG is accelerating its doctor-led mission to enhance the quality of care, deliver eye care for all, and improve quality of life across India.


LANXESS to showcase Biosecurity Solutions at EuroTier 2022
News | November 10, 2022

LANXESS to showcase Biosecurity Solutions at EuroTier 2022

The core of “LANXESS Biosecurity Solutions” is a portfolio of scientifically formulated, highly effective and versatile biocidal products


AGC to establish Life Science Company in 2023
News | November 10, 2022

AGC to establish Life Science Company in 2023

The Group will continue to make proactive investments of its management resources in the life science business


Solvay partners with Ostium in single-use surgical instruments material recycling
Sustainability | November 09, 2022

Solvay partners with Ostium in single-use surgical instruments material recycling

Value chain collaboration aims to foster a circular ecosystem and reduce the carbon footprint of single-use surgical instruments molded in Ixef PARA.


Lupin receives tentative approval from USFDA for Doxycycline Capsules
Drug Approval | November 09, 2022

Lupin receives tentative approval from USFDA for Doxycycline Capsules

Doxycycline Capsules (RLD Oracea) had estimated annual sales of US $215 million in the US


Zydus receives EIR with VAI from USFDA for Moraiya facility
Drug Approval | November 08, 2022

Zydus receives EIR with VAI from USFDA for Moraiya facility

The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)


Tatva Chintan Q2 FY23 revenue down 27%; Net profit down 78%
News | November 07, 2022

Tatva Chintan Q2 FY23 revenue down 27%; Net profit down 78%

Revenue from operations for the half year was Rs. 178.5 crore, declined by 23% whereas net profit for the half year was Rs. 16.9 crore, declined by 70%


Balaxi Pharmaceuticals delivers strong growth in Q2 FY23
News | November 07, 2022

Balaxi Pharmaceuticals delivers strong growth in Q2 FY23

Revenue is up 23% whereas Profit After Tax expands 29% for the company